CONMED (NYSE:CNMD) Updates FY 2026 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 4.480-4.600 for the period, compared to the consensus earnings per share estimate of 4.370. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on CNMD shares. JPMorgan Chase & Co. decreased their price objective on shares of CONMED from $43.00 to $40.00 and set a “neutral” rating on the stock in a research report on Thursday, April 30th. Bank of America restated an “underperform” rating and set a $40.00 price objective on shares of CONMED in a research report on Monday, June 29th. Needham & Company LLC reiterated a “hold” rating on shares of CONMED in a research report on Monday, July 13th. Wells Fargo & Company raised their price target on CONMED from $39.00 to $46.00 and gave the company an “equal weight” rating in a research report on Thursday. Finally, BMO Capital Markets started coverage on CONMED in a research report on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price objective on the stock. Five research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $41.40.

CONMED Trading Down 2.9%

Shares of NYSE:CNMD traded down $1.36 on Friday, reaching $45.62. 68,467 shares of the company traded hands, compared to its average volume of 556,987. The stock has a market capitalization of $1.37 billion, a P/E ratio of 24.66, a price-to-earnings-growth ratio of 3.20 and a beta of 0.93. The business’s 50-day simple moving average is $37.09 and its 200 day simple moving average is $38.42. The company has a current ratio of 2.29, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. CONMED has a 52 week low of $31.44 and a 52 week high of $56.63.

CONMED (NYSE:CNMD) last released its earnings results on Wednesday, July 29th. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.28. CONMED had a return on equity of 14.38% and a net margin of 4.12%.The company had revenue of $343.49 million during the quarter, compared to analyst estimates of $337.60 million. During the same quarter in the previous year, the company posted $1.15 EPS. CONMED’s revenue for the quarter was up .3% on a year-over-year basis. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. As a group, equities analysts anticipate that CONMED will post 4.38 EPS for the current fiscal year.

Trending Headlines about CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q2 results exceeded expectations. CONMED reported adjusted earnings of $1.38 per share versus the $1.10 consensus estimate, while revenue reached $343.5 million, ahead of the $337.6 million forecast. Earnings also increased from $1.15 per share in the prior-year quarter. CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
• Positive Sentiment: Management raised the earnings outlook. CONMED now expects 2026 adjusted EPS of $4.48 to $4.60, above the roughly $4.37 analyst consensus, while targeting 5% to 6% organic growth. Margin expansion and solid international sales provided additional support. CONMED forecasts 2026 adjusted EPS of $4.48 to $4.60 while targeting 5% to 6% organic growth
• Positive Sentiment: Wells Fargo raised its price target for CNMD to $46 from $39, reflecting the improved earnings outlook, although it maintained an Equal Weight rating. Wells Fargo price-target update
• Neutral Sentiment: Piper Sandler reaffirmed its Neutral rating but increased its price target to $45 from $39. The revised target suggests analysts see relatively little near-term upside after the recent rally. Piper Sandler rating update
• Negative Sentiment: Reported sales growth remained subdued. Revenue rose only 0.3% year over year, or declined 0.5% on a constant-currency basis. Organic growth was stronger after excluding discontinued gastrointestinal product offerings, but the strategic exits weigh on headline comparisons and may be contributing to investor caution.

Hedge Funds Weigh In On CONMED

A number of hedge funds have recently modified their holdings of the company. Franklin Resources Inc. bought a new stake in shares of CONMED in the third quarter worth about $281,000. Baird Financial Group Inc. bought a new stake in shares of CONMED in the 2nd quarter worth approximately $243,000. Tower Research Capital LLC TRC grew its position in shares of CONMED by 107.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,248 shares of the company’s stock worth $221,000 after buying an additional 2,205 shares during the last quarter. iSAM Funds UK Ltd bought a new position in shares of CONMED during the second quarter valued at approximately $215,000. Finally, Sherbrooke Park Advisers LLC purchased a new stake in CONMED in the third quarter worth $211,000.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.